Adezkibart

阿德奇拜单抗

Report date: 2026/05/09 20:00:18

Base Information

Drug NameAdezkibart
Drug Alias NameVIB-1116AMG 329HZN-1116
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionFms-related tyrosine kinase 3 ligand modulators
TargetsFms-related tyrosine kinase 3 ligand
Therapy Area/IndicationsAutoimmune DiseasesRheumatic DiseasesSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[16] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesViela Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesRheumatic Diseases
Inactive IndicationsSjogren's Syndrome

Other Information

ATC CodeN/A
Related LinksN/A